Literature DB >> 3531113

Irradiation with misonidazole and hyperbaric oxygen: final report on a randomized trial in advanced head and neck cancer.

R Sealy, S Cridland, L Barry, R Norris.   

Abstract

One hundred and thirty patients with locally advanced squamous carcinoma of the head and neck were treated in a prospective randomized trial to compare conventional irradiation (63.00 Gy in 30 fractions) with a combination sensitizer regimen of misonidazole and hyperbaric oxygen. The drug (2.0 gm/m2) was given with each of six fractions of 6.0 Gy in hyperbaric oxygen at 3 ATA. The results support a previous study and favor the combination at 1 year at better than the 10% level. This regimen could be useful for bulky primary or nodal disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3531113     DOI: 10.1016/0360-3016(86)90168-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Combination therapy: hypoxia modification with radiotherapy for bladder cancer.

Authors:  Mary Gospodarowicz
Journal:  Nat Rev Clin Oncol       Date:  2011-02-01       Impact factor: 66.675

Review 2.  What is the role of hyperbaric oxygen in the management of diabetic foot disease?

Authors:  Magnus Löndahl; Katarina Fagher; Per Katzman
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

Review 3.  Hyperbaric oxygen therapy for malignancy: a review.

Authors:  Jurstine Daruwalla; Chris Christophi
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

Review 4.  Hyperbaric oxygenation for tumour sensitisation to radiotherapy.

Authors:  Michael H Bennett; John Feldmeier; Robert Smee; Christopher Milross
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 5.  Hyperbaric oxygenation for tumour sensitisation to radiotherapy.

Authors:  Michael H Bennett; John Feldmeier; Robert Smee; Christopher Milross
Journal:  Cochrane Database Syst Rev       Date:  2018-04-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.